Why Camp4 Therapeutics Corporation’s (CAMP) Stock Is Up 6.07%
As of Wednesday, September 02, Camp4 Therapeutics Corporation’s CAMP share price has surged by 6.07%, which has investors questioning if this is right time to sell.Jenna Brashear
Stock Evaluator: Camp4 Therapeutics Corporation (CAMP)
Camp4 Therapeutics Corporation CAMP
$3.89
0.09
2.37%
September 3, 2026 12:00:15 PM
EST
Volume: 86,090
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Biotechnology |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-001, which is in a Phase 1/2 clinical trial for the treatment of urea cycle disorders. The company also develops CMP-002 for the treatment of SYNGAP1-related disorders. Camp4 Therapeutics Corporation was formerly known as Marauder Therapeutics, Inc. and changed its name to Camp4 Therapeutics Corporation in March 2018. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Commentary & Analysis
Why Camp4 Therapeutics Corporation’s (CAMP) Stock Is Down 6.27%
As of Monday, August 31, Camp4 Therapeutics Corporation’s CAMP share price has dipped by 6.27%, which has investors questioning if this is right time to buy.Michael Rose
Why Camp4 Therapeutics Corporation’s (CAMP) Stock Is Down 7.17%
As of Monday, August 17, Camp4 Therapeutics Corporation’s CAMP share price has dipped by 7.17%, which has investors questioning if this is right time to buy.Rosalio Madrigal
What You Need to Know About Camp4 Therapeutics Corporation's Q3 Earnings
Camp4 Therapeutics Corporation's fiscal Q3 earnings report was released on Thursday, August 13. Let's dive in to see if (CAMP) missed or beat analyst's expectations.Jenna Brashear
Why Camp4 Therapeutics Corporation’s (CAMP) Stock Is Up 8.39%
As of Wednesday, August 12, Camp4 Therapeutics Corporation’s CAMP share price has surged by 8.39%, which has investors questioning if this is right time to sell.Michael Rose
Financial Summary
| Share Statistics | CAMP | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $238.5 | $288.9 | 29% |
|
| Shares Out (Mil) | 57.9 | 54.0 | 51% |
|
| Institutional Ownership | 97.6% | 93.1% | 75% |
|
| Float (Mil) | 38.5 | 41.4 | 41% |
|
| Beta | na | 0.94 | na |
|
| Avg Daily Volume (000s) | 262 | 480 | 49% |
|
| Price Change (52-week) |
143.6% | 59.9% | 95% |
|
| Growth | CAMP | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 14.1% | na |
|
| Net Income (5yr) | na | (10.1%) | na |
|
| EPS (5yr) | na | 15.9% | na |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | na | (15.6%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 3 | 3 | 3 | |
| Current EPS | ($0.186) | ($1.039) | ($0.795) | |
| Month Ago EPS | ($0.188) | ($0.793) | ($0.779) | |
| # Rev Up | 1 | 1 | 1 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | ($0.177) | ($0.769) | ($0.732) | |
| Year/Year Chg | (67.9%) | (60.7%) | (67.5%) | |
| Financials | CAMP | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $4 | $37 | 5% |
|
| Net Income (TTM) (Mil) | ($107) | ($43) | 10% |
|
| EPS (TTM) | ($2.177) | ($1.500) | 14% |
|
| Operating Cash Flow (TTM) (Mil) | ($29) | ($31) | 13% |
|
| Net Cash Flow (TTM) (Mil) | na | $2 | na |
|
| Long-Term Debt (Q1) (Mil) | $2 | $4 | 19% |
|
| Enterprise Value (Q1) (Mil) | $257 | $190 | 28% |
|
| Valuation | CAMP | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.84 | na |
|
| P/E | na | 20.0 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | CAMP | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (817.7%) | 66.9% | 0% |
|
| Net Margin | na | (74.2%) | na |
|
| ROA | (148.2%) | (47.7%) | 3% |
|
| ROE | (545.9%) | (55.0%) | 1% |
|
| Liabilities to Assets | 100.7% | 29.6% | 94% |
|
| F-Score | 2 | 3 | 7% |
|
Camp4 Therapeutics Corporation did not pass any screens on 9/2/2026.
